Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US

24 Oct 2018 Evaluate

Sun Pharmaceutical Industries has launched its plaque psoriasis treatment drug ‘ILUMYA’ (tildrakizumab-asmn) 100 mg/mL in the United States. ILUMYA is an injectable interleukin-23 (IL-23) inhibitor approved by the USFDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1515.15 -14.55 (-0.95%)
07-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.15
Dr. Reddys Lab 6277.10
Cipla 1388.00
Zydus Lifesciences 980.65
Lupin 1610.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.